The University of Chicago Header Logo

Connection

Olwen Hahn to Ipilimumab

Back to Details
This is a "connection" page, showing publications Olwen Hahn has written about Ipilimumab.
Olwen Hahn
Connection Strength
0.051
Ipilimumab
  1. A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609). Clin Cancer Res. 2022 01 15; 28(2):271-278.
    View in: PubMed
    Score: 0.051
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.